FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) automatically classifies using FRONTEO's natural language processing AI engine "Concept Encoder (trademark: conceptencoder, reading: concept encoder)".・We are pleased to announce that the screening AI system “Mekiki” has been introduced at Chugai Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Osamu Okuda; hereinafter Chugai Pharmaceutical).

　Mekiki uses AI to collect highly specialized information such as disease information and patent information handled by pharmaceutical companies, medical institutions, research institutions, etc., drug safety information, competitive product information, sales and public relations related documents. It is a system that detects and classifies according to the situation, and contributes to the efficiency of document management and examination work, as well as the burden and cost reduction.The target data can be processed in any format, such as document files, e-mails, slide files, etc. It is characterized by supporting technical terms and industry-specific classification and management standards.

　In this introduction, we will use natural language processing AI technology to more reliably detect necessary information in the work of confirming drug safety information with the human eye at Chugai Pharmaceutical's Medical Affairs Division. We will support you.

　FRONTEO will continue to contribute to the promotion of DX (digital transformation) in the medical and pharmaceutical industries and the improvement and efficiency of operations through the provision of high-performance AI systems.

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

* FRONTEO, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.